Journal of Clinical Endocrinology & Metabolism, Vol 76, 819-823, Copyright © 1993 by Endocrine Society

ARTICLES

Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity

F Cordido, A Penalva, C Dieguez and FF Casanueva
Endocrine Section Hospital General de Galicia, Santiago de Compostela, Spain.

GH secretion in response to all provocative stimuli is decreased in patients with obesity. However, the precise mechanism causing this impairment in GH release is unknown. His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) is a synthetic compound that releases GH in a dose-related and specific manner in several species, including man. To gain further insight into disrupted GH secretion in obesity, GHRP-6 and GH-releasing hormone (GHRH) at a dose of 100 micrograms, i.v., were administered either alone or in combination in a group of 19 obese subjects. In a group of obese patients, GHRP-6 induced GH secretion, with a GH peak (mean +/- SEM) of 15.7 +/- 4.4 micrograms/L and an area under the curve (AUC) of 674 +/- 187, which were larger than those after GHRH stimulation (6.8 +/- 1.1 and 412 +/- 71, respectively). Enhancement of the endogenous cholinergic tone was obtained in another group of obese subjects by means of pyridostigmine (120 mg, orally). Pyridostigmine administered 60 min before GHRP-6, increased both the mean GH peak (32.2 +/- 6.9) and the AUC (1413 +/- 537) after GHRP-6 administration. In a separate group of subjects, the combined administration of GHRP-6 and GHRH induced a massive discharge of GH, with individual responses ranging from 14-86 micrograms/L. GHRP-6 plus GHRH induced a mean GH peak of 42.2 +/- 10.9 and an AUC of 1894 +/- 784 (P < 0.05), clearly indicating a potentiating (synergic) action when the two compounds were administered together. These data show that GH responses to GHRP-6 were almost twice those to GHRH in obese patients. The stimulatory effect exerted by pyridostigmine on GHRP-6-induced GH secretion supported the view of increased somatostatinergic tone in obesity. Finally, the massive GH discharge that followed the administration of GHRH plus GHRP- 6 was not observed after any stimulus in obesity, clearly indicating that the impaired GH secretion is a functional and potentially reversible state.

This article has been cited by other articles:

				P. Kok, F. Roelfsema, M. Frolich, J. van Pelt, A. E. Meinders, and H. Pijl Short-Term Treatment with Bromocriptine Improves Impaired Circadian Growth Hormone Secretion in Obese Premenopausal Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3455 - 3461. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				V. S. Bonert, J. D. Elashoff, P. Barnett, and S. Melmed Body Mass Index Determines Evoked Growth Hormone (GH) Responsiveness in Normal Healthy Male Subjects: Diagnostic Caveat for Adult GH Deficiency J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3397 - 3401. [Abstract] [Full Text] [PDF]

				C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF]

				M. Ozata, C. Dieguez, and F. F. Casanueva The Inhibition of Growth Hormone Secretion Presented in Obesity Is Not Mediated by the High Leptin Levels: A Study in Human Leptin Deficiency Patients J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 312 - 316. [Abstract] [Full Text] [PDF]

				J. Z. Kasa-Vubu, A. Barkan, P. Olton, T. Meckmongkol, N. E. Carlson, and C. M. Foster Incomplete Modified Fast in Obese Early Pubertal Girls Leads to an Increase in 24-Hour Growth Hormone Concentration and a Lessening of the Circadian Pattern in Leptin J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1885 - 1893. [Abstract] [Full Text] [PDF]

				M. Maccario, F. Tassone, L. Gianotti, F. Lanfranco, S. Grottoli, E. Arvat, E. E. Muller, and E. Ghigo Effects of Recombinant Human Insulin-Like Growth Factor I Administration on the Growth Hormone (GH) Response to GH-Releasing Hormone in Obesity J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 167 - 171. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				P. F. Catalina, F. Mallo, M. A. Andrade, R. V. García-Mayor, and C. Diéguez Growth Hormone (GH) Response to GH-Releasing Peptide-6 in Type 1 Diabetic Patients with Exaggerated GH-Releasing Hormone-Stimulated GH Secretion J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3663 - 3667. [Abstract] [Full Text]

				D. Micic, V. Popovic, M. Doknic, D. Macut, C. Dieguez, and F. F. Casanueva Preserved Growth Hormone (GH) Secretion in Aged and Very Old Subjects after Testing with the Combined Stimulus GH-Releasing Hormone plus GH-Releasing Hexapeptide-6 J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2569 - 2572. [Abstract] [Full Text]

				R. Roubenoff, L. C. Rall, J. D. Veldhuis, J. J. Kehayias, C. Rosen, M. Nicolson, N. Lundgren, and S. Reichlin The Relationship between Growth Hormone Kinetics and Sarcopenia in Postmenopausal Women: The Role of Fat Mass and Leptin J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1502 - 1506. [Abstract] [Full Text]

				J. Svensson, L. Lönn, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, I. Boseaus, et al. Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 362 - 369. [Abstract] [Full Text]

				A. Leal-Cerro, L. M. Jimenez, R. Astorga, I. Fernandez-Lopez, C. Dieguez, and F. F. Casanueva Acute Pharmacological Reduction of Plasma Free Fatty Acids Enhances the Growth Hormone (GH)-Releasing Hormone-Mediated GH Secretion in Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3165 - 3168. [Abstract] [Full Text] [PDF]

				S. Grottoli, M. Procopio, M. Maccario, M. Zini, S. E. Oleandri, F. Tassone, R. Valcavi, and E. Ghigo In Obesity, Glucose Load Loses Its Early Inhibitory, But Maintains Its Late Stimulatory, Effect on Somatotrope Secretion J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2261 - 2265. [Abstract] [Full Text] [PDF]

				G. Van den Berghe, F. de Zegher, J. D. Veldhuis, P. Wouters, M. Awouters, W. Verbruggen, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, et al. The Somatotropic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2 Infusion J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 590 - 599. [Abstract] [Full Text] [PDF]